In this issue
EMJ interviewed three dermatology experts who highlight the impact that topical clascoterone, a novel androgen receptor inhibiter, could have in reducing acne disease burden.
Rate this content's potential impact on patient outcomes
Average rating 0 / 5. Vote count: 0
No votes so far! Be the first to rate this content.
Latest articles
All articles


We’ve noticed you’re accessing
from North/South America.
from North/South America.